RU2520080C2 - Композиции и мультипараметричекие способы анализа для измерения биологических медиаторов физиологического здоровья - Google Patents

Композиции и мультипараметричекие способы анализа для измерения биологических медиаторов физиологического здоровья Download PDF

Info

Publication number
RU2520080C2
RU2520080C2 RU2009116433/10A RU2009116433A RU2520080C2 RU 2520080 C2 RU2520080 C2 RU 2520080C2 RU 2009116433/10 A RU2009116433/10 A RU 2009116433/10A RU 2009116433 A RU2009116433 A RU 2009116433A RU 2520080 C2 RU2520080 C2 RU 2520080C2
Authority
RU
Russia
Prior art keywords
analytes
sample
analyte
months
collection
Prior art date
Application number
RU2009116433/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2009116433A (ru
Inventor
Эбенезер САТЬЯРАДЖ
Стивен С ХАННА
Original Assignee
Нестек С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нестек С.А. filed Critical Нестек С.А.
Publication of RU2009116433A publication Critical patent/RU2009116433A/ru
Application granted granted Critical
Publication of RU2520080C2 publication Critical patent/RU2520080C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
RU2009116433/10A 2006-10-06 2007-10-04 Композиции и мультипараметричекие способы анализа для измерения биологических медиаторов физиологического здоровья RU2520080C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84992806P 2006-10-06 2006-10-06
US60/849,928 2006-10-06
PCT/US2007/021451 WO2008057160A2 (en) 2006-10-06 2007-10-04 Compositions and multiplex assays for measuring biological mediators of physiological health

Publications (2)

Publication Number Publication Date
RU2009116433A RU2009116433A (ru) 2010-11-20
RU2520080C2 true RU2520080C2 (ru) 2014-06-20

Family

ID=39364961

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009116433/10A RU2520080C2 (ru) 2006-10-06 2007-10-04 Композиции и мультипараметричекие способы анализа для измерения биологических медиаторов физиологического здоровья

Country Status (11)

Country Link
US (2) US20100196880A1 (de)
EP (1) EP2069524A4 (de)
JP (1) JP2010505420A (de)
CN (1) CN101627129B (de)
AU (1) AU2007318208B2 (de)
BR (1) BRPI0717803A2 (de)
CA (1) CA2665164A1 (de)
MX (1) MX2009003583A (de)
RU (1) RU2520080C2 (de)
WO (1) WO2008057160A2 (de)
ZA (1) ZA200903094B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5656209B2 (ja) * 2008-09-26 2015-01-21 独立行政法人産業技術総合研究所 ウシタイレリア症の病態評価を可能とする方法
ES2677944T3 (es) 2009-11-25 2018-08-07 Hologic Inc. Detección de infección intraamniótica
CN103328653A (zh) * 2010-11-24 2013-09-25 霍夫曼-拉罗奇有限公司 用于检测低度炎症的方法
WO2012129312A2 (en) * 2011-03-21 2012-09-27 Laboratory Corporation Of America Holdings Methods and systems for multiple control validation
CA2843473A1 (en) * 2011-08-12 2013-02-21 Alfred Health Method for diagnosis, prognosis or treatment of acute coronary syndrome (acs) comprising measurement of plasma concentration of macrophage migration inhibitory factor (mif)
CN102749448B (zh) * 2012-07-27 2014-07-02 复旦大学附属中山医院 用于评估肺腺癌化疗效果的试剂盒
WO2014037811A2 (en) * 2012-09-07 2014-03-13 The Governors Of The University Of Alberta Methods and compositions for diagnosis of inflammatory liver disease
CN113156138A (zh) * 2013-01-03 2021-07-23 梅索磅秤技术有限公司 测定实验对象组
JP5710666B2 (ja) * 2013-02-25 2015-04-30 敦生 関山 生体負荷の指標剤および生体負荷の測定方法
JP6532456B2 (ja) 2013-10-04 2019-06-19 ライフ テクノロジーズ コーポレーション 終止化学を用いる配列決定における整相効果（ｐｈａｓｉｎｇ ｅｆｆｅｃｔｓ）をモデル化するための方法及びシステム
CN103837687A (zh) * 2014-03-10 2014-06-04 青岛康立泰药业有限公司 使用具有白细胞介素-12受体的细胞检测重组人白细胞介素-12体外活性的方法及应用
US10435747B2 (en) * 2014-08-19 2019-10-08 Arizona Board Of Regents On Behalf Of Arizona State University Radiation biodosimetry systems
BR112017005730B1 (pt) 2014-09-26 2023-12-12 Somalogic Operating Co., Inc Método para triagem de um indivíduo quanto ao risco de um evento cardiovascular ou para predizer a probabilidade que um indivíduo tenha tal evento
JP6959136B2 (ja) 2015-01-23 2021-11-02 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 患者の示差的な栄養所要量の決定方法
ES2952744T3 (es) 2016-12-15 2023-11-03 Nestle Sa Composiciones y procedimientos que modulan los glóbulos blancos o los neutrófilos en un animal de compañía
CN110325106A (zh) * 2017-02-20 2019-10-11 加利福尼亚大学董事会 无症状性脑缺血的血清学测定
US11408885B2 (en) 2017-08-31 2022-08-09 Massachusetts Institute Of Technology Compositions and multiplex assays for characterizing active proteases and their inhibitors
CN112136048A (zh) * 2018-02-21 2020-12-25 艾迪菲斯健康有限公司 测量全身性慢性炎性衰老的方法
RU2698092C1 (ru) * 2018-04-10 2019-08-22 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт общей патологии и патофизиологии" Способ выявления предрасположенности к заболеванию атеросклерозом на основе определения экспрессии генов, вовлеченных в накопление холестерина
JP2022544169A (ja) 2019-08-07 2022-10-17 エディフィス・ヘルス・インコーポレイテッド 心血管疾患の処置および予防
CN110850096B (zh) * 2019-09-29 2023-02-17 瑞博奥(广州)生物科技股份有限公司 生物标记物组及其应用和蛋白芯片、蛋白芯片试剂盒和elisa试剂盒
JP2024504009A (ja) * 2020-12-22 2024-01-30 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 間質性膀胱炎の評価および治療のための方法、キット、および組成物
CN114404601B (zh) * 2022-03-31 2022-06-07 首都医科大学附属北京朝阳医院 MDK抑制剂在制备用于抑制干扰素-γ治疗引起的肿瘤转移的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2171471C2 (ru) * 1995-05-30 2001-07-27 Кортендо АБ Способ диагностики метаболического синдрома и заболеваний, включающих в себя данный синдром

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040225449A1 (en) * 1999-06-28 2004-11-11 Bevilacqua Michael P. Systems and methods for characterizing a biological condition or agent using selected gene expression profiles
US7465540B2 (en) * 2000-09-21 2008-12-16 Luminex Corporation Multiple reporter read-out for bioassays
US20040191775A1 (en) * 2003-03-12 2004-09-30 Spindler Stephen R. Methods of analyzing genes affected by caloric restriction or caloric restriction mimetics
CA2574360A1 (en) * 2004-07-19 2006-01-26 N.V. Nutricia A preparation for use of aspartate for regulating glucose levels in blood

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2171471C2 (ru) * 1995-05-30 2001-07-27 Кортендо АБ Способ диагностики метаболического синдрома и заболеваний, включающих в себя данный синдром

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BAGCHI M. ЕТ AL., DNA microarray technology in the evaluation of weight management potential of a novel calcium-potassium salt of (-)-hydroxycitric acid, TOXICOLOGY MECHANISMS AND METHODS, v.16, no.2-3, 2006, p.129-135. FAN H. ЕТ AL., The transcriptome in blood: challenges and solutions for robust expression profiling, CURRENT MOLECULAR MEDICINE, v.5, 2005, p.3-10. *
NG T.W. ЕТ AL., Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics?, Diabetes, 2005, v.54, no.3, p.795-802. GNINDY S. ЕТ AL., For the Conference participants Definition of metabolic syndrome Report of the National Heart, Lung, and Blood Institute/ American Heart Association Conference on Scientific Issues Related to Definition Circulation, 2004, no.109, p.433-438. *

Also Published As

Publication number Publication date
CA2665164A1 (en) 2008-05-15
MX2009003583A (es) 2009-04-15
CN101627129A (zh) 2010-01-13
EP2069524A2 (de) 2009-06-17
CN101627129B (zh) 2014-07-02
JP2010505420A (ja) 2010-02-25
US20100196880A1 (en) 2010-08-05
WO2008057160A2 (en) 2008-05-15
ZA200903094B (en) 2010-07-28
WO2008057160A3 (en) 2009-05-14
EP2069524A4 (de) 2010-02-24
RU2009116433A (ru) 2010-11-20
AU2007318208A1 (en) 2008-05-15
BRPI0717803A2 (pt) 2013-11-19
AU2007318208B2 (en) 2013-10-24
US20120122717A1 (en) 2012-05-17

Similar Documents

Publication Publication Date Title
RU2520080C2 (ru) Композиции и мультипараметричекие способы анализа для измерения биологических медиаторов физиологического здоровья
Torok et al. Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles
Bauer et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus
Blanchard et al. A striking local esophageal cytokine expression profile in eosinophilic esophagitis
Shimada et al. Profiling biomarkers in gingival crevicular fluid using multiplex bead immunoassay
US20110251099A1 (en) SERUM MARKERS PREDICTING CLINICAL RESPONSE TO ANTI-TNFa ANTIBODIES IN PATIENTS WITH ANKYLOSING SPONDYLITIS
US20130267039A1 (en) Single Molecule Assays
Kastenbauer et al. Patterns of protein expression in infectious meningitis: a cerebrospinal fluid protein array analysis
EP3088897A1 (de) Verfahren zur vorhersage der wirksamkeit eines biologischen präparats bei rheumatoider arthritis
Batra et al. Comparative evaluation of Gingival Crevicular Fluid (GCF) levels of Interleukin-34 levels in periodontally healthy and in patients with chronic and aggressive periodontitis-A cross-sectional study
KR20190117555A (ko) 무증상 뇌 허혈에 대한 혈청학적 분석
WO2015193427A1 (en) Determination and analysis of biomarkers in clinical samples
US20070141627A1 (en) Systemic Lupus Erythematosus
US10280466B2 (en) Method and kit for dynamic gene expression monitoring
US20210018514A1 (en) Method of predicting and determining therapeutic effect on rheumatoid arthritis due to biological formulation
US20040072237A1 (en) Use of cytokines secreted by dendritic cells
Meens Miller Identifying salivary biomarkers associated with prolonged sitting
RU2815973C2 (ru) Нарушения, опосредованные интерфероном i типа
US20230358759A1 (en) Cytokine based assessment of recipient ability to respond to stem cell therapy for cartilage regeneration
EP3356548B1 (de) Immunologische signaturen und parameter zur vorhersage therapeutischer reaktionen auf anti-tnf-therapie

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20161005